Scholarlink

Introduction <p>Psoriasis is a chronic immune-mediated skin inflammatory disorder characterized by aberrant keratinocyte proliferation with increased inflammation. Linalool and Linalyl acetate (LLA) are natural phytomolecules with reported anti-psoriatic potential, while Salicylic acid (SA) acts as keratolytic agent promoting plaque desquamation.</p> Objectives <p>This study aimed to evaluate the anti-psoriatic efficacy of non-steroidal plant lead containing 2% LLA + 3.5% SA in comparison with a commercial formulation containing 0.1% mometasone furoate (MSF) + 3.5% SA and assess the therapeutic potential of LLA monotherapy (5.5%) to determine whether LLA alone could serve as an effective anti-psoriatic agent.</p> Methods <p>An imiquimod (IMQ)-induced psoriasis-like model was established in BALB/c mice, and evaluation included ear thickness, body weight, spleen index, PASI score, CosCam score, ELISA, and histopathological analysis. The dermal toxicity studies of LLA in CF rats and New Zealand white rabbits were also conducted in accordance with OECD guidelines.</p> Key finding <p>The LLA-based treatments significantly ameliorated psoriasis-like symptoms compared with the commercial formulation. Notably, the 5.5% LLA treatment demonstrated marked therapeutic effect, showing greater PASI and CosCam score recovery (PASI: 90.00 ± 3.12%; CosCam: 89.70 ± 3.29%) with significant epidermal normalization, and reduction of inflammatory cytokines in the IMQ-induced model. Dermal toxicity studies further confirmed the dermal and systemic safety of LLA.</p> Conclusion <p>This study highlights the potential of 5.5% LLA as an effective and safer alternative to the commercially available product (0.1% MSF + 3.5% SA) for treating psoriasis.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Linalool-Linalyl Acetate as a Non-steroidal Alternative to Mometasone-Salicylic Acid Therapy in Imiquimod-induced Psoriasis Model

  • 期刊论文

  • 发表日期：

    2026年6月26日

查看全文
  • Debasish Sahoo,
  • Vipin Kumar Singh,
  • Km. Sushmita,
  • Debabrata Chanda,
  • Narayan Prasad Yadav

摘要

Introduction

Psoriasis is a chronic immune-mediated skin inflammatory disorder characterized by aberrant keratinocyte proliferation with increased inflammation. Linalool and Linalyl acetate (LLA) are natural phytomolecules with reported anti-psoriatic potential, while Salicylic acid (SA) acts as keratolytic agent promoting plaque desquamation.

Objectives

This study aimed to evaluate the anti-psoriatic efficacy of non-steroidal plant lead containing 2% LLA + 3.5% SA in comparison with a commercial formulation containing 0.1% mometasone furoate (MSF) + 3.5% SA and assess the therapeutic potential of LLA monotherapy (5.5%) to determine whether LLA alone could serve as an effective anti-psoriatic agent.

Methods

An imiquimod (IMQ)-induced psoriasis-like model was established in BALB/c mice, and evaluation included ear thickness, body weight, spleen index, PASI score, CosCam score, ELISA, and histopathological analysis. The dermal toxicity studies of LLA in CF rats and New Zealand white rabbits were also conducted in accordance with OECD guidelines.

Key finding

The LLA-based treatments significantly ameliorated psoriasis-like symptoms compared with the commercial formulation. Notably, the 5.5% LLA treatment demonstrated marked therapeutic effect, showing greater PASI and CosCam score recovery (PASI: 90.00 ± 3.12%; CosCam: 89.70 ± 3.29%) with significant epidermal normalization, and reduction of inflammatory cytokines in the IMQ-induced model. Dermal toxicity studies further confirmed the dermal and systemic safety of LLA.

Conclusion

This study highlights the potential of 5.5% LLA as an effective and safer alternative to the commercially available product (0.1% MSF + 3.5% SA) for treating psoriasis.